Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Sep 20 · above the Ichimoku cloud · RSI 46 · MACD below its signal
None of the 29 investors followed here reported a position in 2196.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 2196.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for 2196.HK.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.5 | -2.0 | -1.0 | -3.6 | -10.9 | -11.2 | 8.7 | -2.6 | 15.5 | -6.8 | −11.9% | ||
| 2025 | -7.0 | 16.0 | -1.7 | -6.6 | 17.6 | 2.7 | 13.5 | 13.5 | 18.6 | -7.6 | -11.9 | -6.9 | +38.6% |
| 2024 | -22.0 | 6.8 | -9.6 | -3.8 | -0.6 | 8.0 | -1.8 | -4.0 | 25.0 | -5.0 | -3.2 | -1.5 | −17.1% |
| 2023 | 0.8 | -8.9 | -2.8 | 0.2 | -4.7 | -1.9 | -1.9 | -10.0 | -0.3 | -2.0 | -4.2 | -1.6 | −32.0% |
| 2022 | -9.2 | 0.3 | 22.4 | -11.5 | -2.5 | -12.1 | -2.2 | -10.7 | -24.9 | 4.1 | 30.2 | -3.1 | −27.2% |
| 2021 | -5.5 | 4.6 | -9.4 | 48.9 | 31.0 | -3.0 | 13.4 | -29.8 | -19.7 | -8.4 | 9.9 | -14.9 | −7.3% |
| 2020 | -11.1 | 5.0 | 16.2 | 16.1 | -16.9 | 5.3 | 41.5 | -10.6 | -1.8 | -0.9 | 2.4 | 13.7 | +57.7% |
| 2019 | 3.7 | 16.8 | 1.8 | -4.9 | -14.5 | 2.6 | -0.8 | -0.6 | -9.7 | 5.5 | -0.9 | 6.8 | +2.2% |
| 2018 | -9.4 | 0.2 | 5.8 | -10.9 | 17.0 | -14.3 | -13.0 | -15.4 | -2.7 | -23.8 | 14.9 | -14.8 | −54.1% |
| 2017 | 9.1 | 3.1 | 7.1 | 2.6 | 1.7 | 1.3 | -5.5 | 2.8 | 10.2 | 20.2 | -3.2 | 33.0 | +111.2% |
| 2016 | -17.6 | -2.8 | 18.8 | -1.4 | -4.3 | -6.4 | 0.6 | 18.3 | 7.1 | -1.0 | 2.3 | -2.7 | +5.6% |
| 2015 | 0.5 | -8.0 | 0.2 | 14.3 | 13.0 | -13.9 | -20.0 | -1.5 | 7.1 | 4.1 | -0.6 | -10.4 | −19.4% |
| 2014 | 2.1 | 15.9 | -2.4 | -3.0 | 9.9 | 0.3 | -10.9 | -2.1 | -0.6 | 11.4 | -0.4 | 0.4 | +19.5% |
| 2013 | -0.9 | 3.3 | 16.7 | -0.1 | -2.1 | -7.6 | 7.3 | -6.8 | 6.8 | 29.9 | 13.2 | 17.6 | +99.2% |
| 2012 | -0.2 | 5.4 | +5.2% |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Buy / hold / sell counts
No recent headlines.